
0:00
22:37
Dr. Yusaf (PJ) Saleeby shares insights from his practice in 2025 regarding Low Dose Naltrexone (LDN). He discusses patient sensitivity, optimal starting doses, and LDN's efficacy for various conditions including Lyme, cancer, and autoimmune diseases. The conversation also delves into Mast Cell Activation Syndrome (MCAS) and the critical role of informed clinicians in its management.
Flere episoder fra "The LDN Radio Show About Low Dose Naltrexone"



Gå ikke glip af nogen episoder af “The LDN Radio Show About Low Dose Naltrexone” - abonnér på podcasten med gratisapp GetPodcast.








